Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro

Cellular Immunology

Volumn 257, Issue 1-2, 2009, Pages 23-31

  Delirezh, Nowruz ^a   Moazzeni, Seyed Mohammad ^b   Shokri, Fazel ^c   Shokrgozar, Mohammad Ali ^d   Atri, Morteza ^e   Kokhaei, Parviz ^f  

^a URMIA UNIVERSITY   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d PASTEUR INSTITUTE OF IRAN   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f SEMNAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Apoptotic Tumor cells; Breast cancer; Dendritic cells; In vitro; T cell response

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 4;

ADULT; APOPTOSIS; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DENDRITIC CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MONOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR CELL;

ADULT; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; INTERLEUKIN-4; K562 CELLS; MIDDLE AGED; T-LYMPHOCYTES, CYTOTOXIC;

EID: 65049090192     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2009.02.002     Document Type: Article

References (43)

1. In: Ries L.A.G., Kosary C.L., Hankey B.F., and Miller B.A. (Eds). SEER Cancer Statistics Review, 1973-1995 (1998), National Cancer Institute, Bethesda, MD
2. Curigliano G., Spitaleri G., Dettori M., Locatelli M., Scarano E., and Goldhirsch A. Vaccine immunotherapy in breast cancer treatment: promising, but still early. Expert Rev. Anticancer Ther. 7 9 (2007) 1225-1241
3. Adams S., O'Naill D.W., and Bhardwaj N. Recent advances in dendritic cell biology. J. Clin. Immunol. 25 2 (2005) 87-98
4. Brossart P., Zobywalski A., Grunebach F., Behnke L., Stuhler G., Reichardt V.L., Kanz L., and Brugger W. Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin-10 on T-cell stimulatory capacity of dendritic cells. Cancer Res. 60 (2000) 4485-4492
5. Cella M., Sallusto F., and Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol. 9 (1997) 10-16
6. McDermott R.S., Beuvon F., Pauly M., Pallud C., Salomon A.V., Mosseri V., Pouillart P., and Scholl S.M. Tumor antigen and antigen-presenting capacity in breast cancer. Pathobiology 3 70 (2002) 324-332
7. Tsuge T., Yamakawa M., and Tsukamoto M. Infiltrating dendritic/Langerhans cells in primary breast cancer. Breast Cancer Res. Treat. 59 (2000) 141-152
8. Saito H., Frleta D., Dubsky P., and Paluka A.K. Dendritic cell-based vaccination against cancer. Hematol. Oncol. Clin. North Am. 20 3 (2006) 689-710
9. Fazle Akbar S.M., Abe M., Yoshida O., Murakami H., and Onji M. Dendritic cell-based therapy as a multidisciplinary approach to cancer treatment: present limitations and future scopes. Curr. Med. Chem. 13 26 (2006) 3113-3119
10. Zhang Y., Ma B., Zhou Y., Zhang M., Qin X., Sui Y., Zhang X., and Fan Q. Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells. Breast Cancer Res. Treat. 105 3 (2007) 277-286
11. Tuyaerts S., Aerts J.L., Corthals J., Neyns B., Heirman C., Breckpot K., Thielemans K., and Bonehill A. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol. Immunother. 56 10 (2007) 1513-1537
12. Vilella R., Benitez D., Mila J., Lozano M., Vilana R., Pomes J., Tomas X., Consta J., Vilata A., Malvehy J., Puing S., Mellado B., Marti R., and Castel T. Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate. Cancer Immunol. Immunother. 53 (2004) 651-659
13. Ritchie D., Hermans J., Yang J., Walton J., Matthews K., Carter J., Findlay M., Dady P., Rawson P., and Ronchese F. Autologous dendritic cells pulsed with eluted peptide as immunotherapy for advanced B-cell malignancies. Leuk. Lymphoma 47 4 (2006) 577-579
14. Inzkireli N., Guckel B., Sohn C., Wallwiener D., Bastert G., and Lindner M. Antigen loading of dendritic cells with apoptotic tumor cell-preparations is superior to that using necrotic cells or tumor lysates. Anticancer Res. 27 4B (2007) 2121-2129
15. Galea-Lauri J., Darling D., Mufti G., Harrison P., and Farzaneh F. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigen: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol. Immunother. 51 (2002) 299-310
16. Albert M.L., Sauter B., and Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392 (1998) 86-89
17. Henry F., Boisteau O., Betaudeau L., Lieubeau B., Meflah K., and Gregoire M. Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines. Cancer Res. 59 (1999) 3329-3332
18. Mellman J. Antigen processing and presentation by dendritic cells: cell biological mechanisms. Adv. Exp. Med. Biol. 560 (2005) 63-67
19. Labarriere N., Bretaudeau L., Gervous N., Boddner M., Bougras G., Diez E., Lang F., Gregoire M., and Jotereau F. Apoptotic body-loaded dendritic cells efficiently cross-prine cytotoxic T lymphocytes specific for NA17-A antigen but not for Melan-A/Mart-1 antigen. Int. J. Cancer 101 (2002) 280-286
20. Speirs A.R., Waiton D.S., and Atkin S.L. Short-term primary culture of epithelial cells derived from human breast tumors. Br. J. Cancer 78 11 (1998) 1421-1429
21. Meijer A.E., Backbro Saeidi A.B., and Zelenskaya A. Influence of dose-rate post-irradiation incubation time and growth factors on interphuse cell death by apoptosis and clonogenic survival of human peripheral lymphocytes. Int. J. Rad. Biol. 75 10 (1999) 1265-1273
22. Liegler T.J., Hyan W., Benedictyen T.S., and Stites D.P. Detection and quantification of live, apoptotic and necrotic human peripheral lymphocytes by single laser flow cytometry. Clin. Lab. Immunol. (1995) 369-376
23. Berger T.G., Feuerstein B., Strasser E., Hirsch U., Schreiner D., Schuler G., and Schuler-Thurne B. Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell. J. Immunol. Methods 268 (2002) 131-140
24. Fischer K., and Mackensen A. The flow cytometric PKH-26 assay for the determination of T cell mediated cytotoxic activity. Methods 31 (2003) 135-142
25. Huang A.Y., Golumbek P., Ahmadzadeh M., Jaffee E., Paradoll D., and Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264 (1994) 961-965
26. Pinzon-Charry A., Shmidt C., and Lopez J.A. Dendritic cell immunotherapy for breast cancer. Expert Opin. Biol. Ther. 6 6 (2006) 591-604
27. Campbell-Anson R.E., Kentor D., Wang Y.J., Bushnell K.M., Li Y., Vence L.M., and Radvanyi L.G. A new approach for the large-scale generation of mature dendritic cells from adherent PBMC using roller bottle technology. J. Immune Based Ther. Vaccines 6 (2008) 3
28. Zhang S., Wing Q., and Miao S. Review: dendritic cell-based vaccine in the treatment of patients with advanced melanoma. Cancer Biother. Radiopharm. 22 4 (2007) 501-507
29. Abdel-Wahab Z., DeMatos P., Hester D., Dong X.D., and Seigler H.F. Human dendritic cells pulsed with either melanoma tumor cell lysate or the gp100 peptide (280-288) induce pairs of T-cell culture with similar phenotype and lytic activity. Cell. Immunol. 186 (1998) 63-67
30. + cytotoxic T lymphocytes from patients with locally advanced breast cancer by antigen pulsed autologous dendritic cells. J. Surg. Res. 12 (2003) 189-197
31. Ebstein F., Sapede C., Royer P.J., Marcq M., Ligeza-Poisson C., Barbieux I., Cellerin L., Dabouis G., and Grigoire M. Cytotoxic T cell responses against mesothelioma by apoptotic cell pulsed dendritic cells. Am. J. Res. Crit. Care Med. 169 (2004) 1322-1330
32. Hatakeyama N., Tamura Y., Sahara H., Suzuki N., Suzuki K., Hori T., Mizue N., Torigoe T., Tsutsumi H., and Sato N. Induction of autologous CD4- and CD8-mediated T-cell responses against acute lymphocytic leukemia cell line using apoptotic tumor cell-loaded dendritic cells. Exp. Hematol. 34 2 (2006) 197-207
33. Goldszmid R.S., Idoyaga J., Bravo A.I., Steinman R., Mordah J., and Wainstok R. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. J. Immunol. 171 11 (2003) 5940-5947
34. Spisek R., Chevallier P., Morineau N., Milpied N., Avet-Loiseau H., Harossous J.L., Meflah K., and Gregoire M. Induction of leukemia-specific cytotoxic response by cross presentation of late apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin. Caner Res. 62 (2002) 2861-2868
35. Schnurr M., Scholz C., Rothenfusser S., Galambos P., Dauer M., Robe J., Endres S., and Eigler A. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and γδ T cells. Cancer Res. 62 (2002) 2347-2352
36. Chang J.W.C., Peng M., Vaquerano J.E., Zhou Y.M., Clinton R.A., Hyun W.C., Giedlin M.A., and Leong S.P.L. Induction of Th1 response by dendritic cells pulsed with autologous melanoma apoptotic bodies. Anticancer Res. 20 (2000) 1329-1336
37. Kokhaei P., Rezvany M.R., Virving L., Choudhury A., Rabbani H., Osterborg A., and Mellstedt H. Dendritic cells loaded with apoptotic tumor cells induce a stronger T cell response that dendritic cell tumor hybrids in B-CLL. Leukemia 17 (2003) 894-899
38. Gutza E., and Okada C.Y. Tumor cell lysate pulsed dendritic cells are more effective than Id protein vaccines for active immunotherapy of T cell lymphoma. J. Immunol. 69 (2002) 5227-5235
39. Kobayashi T., Shinohara H., Toyoda M., Iwamoto S., and Tanigawa N. Regression of lymph node metastases by immunotherapy using autologous breast tumor lysate pulsed dendritic cells, report of a case. Surg. Today 31 (2001) 513-516
40. Jenne L., Arrighi J.F., Jomuleit H., Saurat J.H., and Hauser C. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis. Cancer Res. 60 (2000) 4446-4452
41. Lauri G., Wells J.W., Darling D., Harrison P., and Farzaneh F. Strategies for antigen choice and priming of dendritic cells influence polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination. Cancer Immunol. Immunother. 53 11 (2004) 963-977
42. Ghosh P., Komschlies K.L., Cippitelli M., Longo D.L., and Sublesli J. Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth. J. Natl. Cancer Inst. 87 (1995) 1478-1483
43. Rieser C., Romaner R., Holtl L., and Rogtsch H. Mature dendritic cells induce T helper type 1 dominant immune responses in patients with metastatic renal cell carcinoma. Urol Int. 63 (1999) 151-159